Mankind Pharma Ltd Financials
Company Logo

Mankind Pharma Ltd Financial Statement

Mankind Pharma Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Mar 2025
Revenue2345.91
Operating Expense1649.67
Net Profit382.46
Net Profit Margin16.30
Earning Per Share9.27
EBIDTA743.02
Effective Tax Rate13.37

Mankind Pharma Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual9,264.81
Operating Expenses Annual6,939.70
Operating Profit Annual2,591.74
Interest Annual14.57
Depreciation155.62
Net Profit Annual1,823.41
Tax Annual436.16

Mankind Pharma Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning134.13
Cash Flow from Operations1,982.97
Cash Flow from Investing-1,919.22
Cash Flow from Financing-8.68
Cash Flow at the End189.20

Mankind Pharma Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)27.98
PBIT Margin (%)24.55
PBT Margin (%)22.92
Net PROFIT Margin (%)19.68
Return On Networth / Equity (%)20.95
Return On Networth /Employed (%)25.77
Return On Assets (%)20.67
Total Debt / Equity (X)TBA
Asset Turnover Ratio (%)1.05

Mankind Pharma Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual3,473.77
Total Current Assets Annual5,490.41
Non Current Assets Annual5,927.30
Total Shareholders Funds Annual9,623.81
Total Assets Annual11,417.71

Mankind Pharma Ltd Earning Calls

EPS (INR)

Expected

10.20

Reported

10.19

Surprise

-0.10%

Dec 2024

EPS beaten by -0.10%

Sep 2024

EPS beaten by -0.32%

Jun 2024

EPS beaten by 0.00%

FAQS on Mankind Pharma Ltd Financials

As of Jun 27, 2025, Mankind Pharma Ltd has a market capitalization of 99,973.97 Cr. Value Research classifies it as a Large-Cap company.

Yes, Mankind Pharma Ltd is with a debt-to-equity ratio of 0.50.

In FY 2024 , Mankind Pharma Ltd recorded a total revenue of approximately 9,497.80 Cr marking a significant milestone in the company's financial performance.

Mankind Pharma Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately Infinity% and 0.1% annually, respectively..

Mankind Pharma Ltd's current PE ratio is 51.39.

Mankind Pharma Ltd's ROCE averaged 18.8% from the FY ending March 2023 to 2025, with a median of 20.4%. It peaked at 23.7% in March 2024, reflecting strong capital efficiency over the period..

Mankind Pharma Ltd's latest EBIT is Rs. 2,738.98 Cr, surpassing the average EBIT of Rs. 2,211.54 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions